NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT04211337,A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer,https://clinicaltrials.gov/study/NCT04211337,LIBRETTO-531,ACTIVE_NOT_RECRUITING,The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.,YES,Medullary Thyroid Cancer,DRUG: Selpercatinib|DRUG: Cabozantinib|DRUG: Vandetanib,"Progression Free Survival (PFS) by Blinded Independent Central Review (BICR), PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria, or death from any cause in the absence of BICR-documented progressive disease.

Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions., Baseline to Progressive Disease or Death from Any Cause, Whichever Occurs First, Up to 39 Months","Treatment Failure-Free Survival (TFFS) by Blinded Independent Committee Review (BICR), TFFS by BICR is defined as the time from randomization to the first occurrence of:

* documented radiographic disease progression per RECIST 1.1 as assessed by BICR; or
* unacceptable toxicity leading to treatment discontinuation as assessed by the investigator.

Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

To qualify as an event, the toxicity must be from an intolerable AE (defined as any study drug-related AE that meets protocol guidance for treatment discontinuation, with the exception of alopecia); or death (due to any cause)., Baseline to Progressive Disease, Unacceptable Toxicity or Death from Any Cause Up to 39 Months|Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR, ORR is defined as the number of participants who achieved the best overall response (BOR) of CR or PR divided by the total number of participants randomized to each treatment arm. ORR per RECIST 1.1 as assessed by BICR., Baseline through Disease Progression or Death Up to 39 Months|Duration of Response (DoR) by BICR, DoR by BICR is defined as the time from the date that measurement criteria for complete response (CR) or partial response (PR) (whichever is first recorded) are first met by the BICR or investigator assessment, as applicable, until the first date that disease is recurrent or documented disease progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions., Date of CR or PR to Date of Disease Progression or Death Due to Any Cause Up to 39 Months|Overall Survival (OS), Overall survival (OS) is defined as the time from randomization until death from any cause. If the participant is alive or lost to follow-up at the time of data analysis, OS data will be censored on the last date the participant is known to be alive., Baseline|PFS2 by Investigator, Progression-free survival 2 (PFS2) is defined as the time from randomization to disease progression (radiographic or symptomatic progression as determined by the investigator) on the next line of treatment or death from any cause in the absence of observed disease progression. If the participant is alive at the cutoff for analysis, and disease progression has not been observed, PFS2 data will be censored on the latest date of last progression-free assessment or start of the next line of treatment., Baseline|Comparative Tolerability: Number of Weeks With High Side Effect Bother Based Score of 3 or 4 on the Functional Assessment of Cancer Therapy Item GP5 (FACT-GP5), Comparative tolerability defined as a comparison of the proportion of time on treatment with high side effect bother as assessed by the FACT-GP5. The FACT-GP5 is a single question used to assess the overall bother of the treatment side effects. It is scored using a 5-point rating scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; and 4 = very much), where lower scores reflect less bother from treatment side effects.

Time with high side effect bother (i.e.) score of 3 or 4 is reported here and was derived as follows: cumulative amount of time, in weeks, during which a participant reports high side effect bother divided by the total duration of therapy (weeks), derived as (date of last study treatment dose - date of first study treatment dose + 1) divided by 7., Baseline to Progressive Disease, Unacceptable Toxicity or Death from Any Cause Up to 39 Months|The Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants With RET-Positive Specimens as Called by the Central Lab, Which is Also RET-Positive as Called by a Local Lab (Positive Percent Agreement), Baseline",,"Loxo Oncology, Inc.",Eli Lilly and Company,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,291,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,17478|J2G-MC-JZJB|2019-001978-28,2020-02-11,2023-05-22,2026-02,2019-12-26,2024-06-13,2025-03-25,"University of Alabama at Birmingham, Birmingham, Alabama, 35249, United States|City of Hope National Medical Center, Duarte, California, 91010-0269, United States|UCLA Hematology/Oncology - Westwood (Building 100), Los Angeles, California, 90095, United States|University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento, California, 95817, United States|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, 90502, United States|Emory University, Atlanta, Georgia, 30322, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10017, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, 45219, United States|The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, 19104, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19114, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|University of Wisconsin Hospitals and Clinics, Madison, Wisconsin, 53792, United States|Royal North Shore Hospital, St Leonards, New South Wales, 2065, Australia|The Alfred Hospital, Melbourne, Victoria, 3004, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3050, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, 6009, Australia|Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman, Liège, 4000, Belgium|Oncocentro, Belo Horizonte, Minas Gerais, 30380-680, Brazil|Hospital de Cancer de Londrina, Londrina, Paraná, 86015-520, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90035-903, Brazil|Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, São Paulo, 14784400, Brazil|Centro de Pesquisa Sao Lucas, Campinas, São Paulo, 13060-904, Brazil|Hospital de Clínicas de Ribeirão Preto, Ribeirão Preto, São Paulo, 14051-140, Brazil|Hospital Sírio Libanês, Sao Paulo, São Paulo, 01308-060, Brazil|Instituto D'Or de Pesquisa e Ensino (IDOR), Sao Paulo, São Paulo, 04543-000, Brazil|Instituto Nacional de Câncer - INCA, Rio de Janeiro, 20230-130, Brazil|Grupo Oncoclínicas Botafogo, Rio de Janeiro, 22250-905, Brazil|Grupo COI - Clínicas Oncológicas Integradas, Rio de Janeiro, 22775-001, Brazil|Icesp - Instituto Do Câncer Do Estado de São Paulo, São Paulo, 01246-000, Brazil|Centro Paulista de Oncologia Clínica, São Paulo, 01452-000, Brazil|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada|Anhui Provincial Hospital, Hefei, Anhui, 230071, China|Beijing Tongren Hospital affiliated to Capital Medical University, Beijing, Beijing, 100730, China|Chongqing University Cancer Hospital, Chongqing, Chongqing, 400030, China|The First Affiliated Hospital Of Fujian Medical University, Fuzhou, Fujian, 350005, China|Gansu Cancer Hospital, Lanzhou, Gansu, 730050, China|Sun Yat-Sen University Cancer Centre, Guangzhou, Guangdong, 510060, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|Henan Cancer Hospital, Zhengzhou, Henan, 450008, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, 210000, China|Jilin Cancer Hospital, Changchun, Jilin, 132000, China|Jinan Central Hospital, Jinan, Shandong, 250013, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200032, China|West China Hospital, Sichuan University, Cheng Du, Sichuan, 610041, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, 300060, China|First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, 310014, China|Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, 310016, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|Fakultní nemocnice Brno Bohunice, Brno, Brno-město, 625 00, Czechia|Fakultni nemocnice Motol, Praha, Praha 5, 150 06, Czechia|Fakultni nemocnice Olomouc, Olomouc, 779 00, Czechia|Centre Paul Strauss, Strasbourg, Alsace, 67065, France|Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, Aquitaine, 33076, France|Assistance Publique Hôpitaux de Marseille - Hôpital Nord, Marseille, Bouches-du-Rhône, 13915, France|Centre François Baclesse, Caen, Calvados, 14076, France|Centre Georges François Leclerc, Dijon, Côte-d'Or, 21079, France|Institut Claudius Regaud, Toulouse, Haute-Garonne, 31059, France|Centre Hospitalier Universitaire d'Angers, Angers, Maine-et-Loire, 49933, France|Hopital Claude Huriez - CHU de Lille, Lille, Nord, 59037, France|Pitie Salpetriere University Hospital, Paris, Orne, 75013, France|Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne, Clermont-Ferrand, Puy-de-Dôme, 63011, France|Centre Leon Berard, Lyon, Rhône-Alpes, 69008, France|Gustave Roussy, Villejuif, Val-de-Marne, 94800, France|Klinikum der Universität München Großhadern, München, Bayern, 81337, Germany|Klinikum der Universität München Großhadern, Würzburg, Bayern, 97080, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, 30625, Germany|Universitaetsklinikum Essen, Essen, Nordrhein-Westfalen, 45122, Germany|Universitätsmedizin Johannes Gutenberg Universität Mainz, Mainz, Rheinland-Pfalz, 55131, Germany|Otto-von-Guericke-Universität Magdeburg, Magdeburg, Sachsen-Anhalt, 39120, Germany|Charité Universitaetsmedizin Berlin - Campus Mitte, Berlin, 10117, Germany|Hämato-Onkologie Hamburg, Prof. Laack und Partner, Hamburg, 20251, Germany|Alexandra Hospital, Athina, Attikí, 115 28, Greece|University General Hospital of Heraklion, Heraklion, Irakleío, 711 10, Greece|European Interbalkan Medical Center, Thessaloníki, Thessaloniki, 570 01, Greece|Regional Cancer Centre - Thiruvananthapuram, Thiruvananthapuram, Kerala, 695011, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, 422001, India|Grant Medical Foundation - Ruby Hall Clinic, Pune, Maharashtra, 411001, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, 411004, India|Apollo Gleneagles Hospitals Kolkata, Kolkata, West Bengal, 700054, India|Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, 160012, India|Rabin Medical Center, Petah-Tikva, HaMerkaz, 4941492, Israel|Sheba Medical Center, Ramat Gan, HaMerkaz, 5265601, Israel|Hadassah Medical Center, Jerusalem, Yerushalayim, 9112001, Israel|University of Naples Federico II, Napoli, Campania, 80131, Italy|Policlinico Umberto I, Roma, Lazio, 00161, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Lombardia, 20133, Italy|Istituto Auxologico Italiano, Milan, Milano, 20122, Italy|Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Piemonte, 10126, Italy|Istituto Nazionale Tumori Regina Elena, Rome, Roma, 00144, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Toscana, 56124, Italy|Ospedale Le Scotte, Siena, Toscana, 53100, Italy|Istituto Oncologico Veneto IRCCS, Padova, Veneto, 35128, Italy|Azienda Ospedaliera Garibaldi, Catania, 95124, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, 464-8681, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, 060-8648, Japan|Kobe University Hospital, Kobe, Hyogo, 650-0017, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, 236-0004, Japan|Osaka University Hospital, Suita, Osaka, 565-0871, Japan|Japanese Foundation for Cancer Research, Koto, Tokyo, 135-8550, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, 810-8563, Japan|Chungbuk National University Hospital, Chungbuk, Chungcheongbuk-do [Chungbuk], 28644, Korea, Republic of|National Cancer Center, Goyang-si, Kyǒnggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Kyǒnggi-do, 13620, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 3080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul-teukbyeolsi [Seoul], 3722, Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], 6351, Korea, Republic of|Maastricht UMC+, Maastricht, Limburg, 6229 HX, Netherlands|Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, Noord-Holland, 1066 CX, Netherlands|Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, 2333 ZA, Netherlands|University Medical Center Groningen, Groningen, 9713 GR, Netherlands|Narodowy Instytut Onkologii - Oddzial w Gliwicach, Gliwice, Śląskie, 44-101, Poland|Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Kielce, Świętokrzyskie, 25-734, Poland|Clinic Evimed, Chelyabinsk, Chelyabinskaya Oblast', 454048, Russian Federation|A. Tsyb Medical Radiological Research Center - branch of the National Medical Research Radiological, Obninsk, Kalužskaja Oblast', 249036, Russian Federation|Fed State Budgetary Inst ""N.N. Blokhin Med Center of Oncology"" MHRF, Moscow, Moskva, 115478, Russian Federation|Endocrinology Research Center of Rosmedtechnologies, Moscow, Moskva, 117292, Russian Federation|Saint Petersburg State University, Saint Petersburg, Sankt-Peterburg, 190020, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary, Saint Petersburg, Sankt-Peterburg, 198255, Russian Federation|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], 8035, Spain|Instituto Catalan de Oncologia - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Catalunya [Cataluña], 8907, Spain|Institut Català d'Oncologia (ICO) - Girona, Girona, Girona [Gerona], 17007, Spain|Clinica Universidad de Navarra, Madrid, Madrid, Comunidad De, 28027, Spain|Hospital Universitario Ramón y Cajal, Madrid, Madrid, Comunidad De, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, Madrid, Comunidad De, 28041, Spain|Hospital Universitario La Paz, Madrid, Madrid, Comunidad De, 28046, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Málaga, 29010, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, 31008, Spain|Hospital General Universitario Gregorio Marañon, Madrid, 28009, Spain|Hospital Clinico San Carlos, Madrid, 28040, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain|Velindre Cancer Centre, Cardiff, Cardiff [Caerdydd Gb-crd], CF14 2TL, United Kingdom|Weston Park Hospital, Sheffield, England, S10 2SJ, United Kingdom|Gartnavel General Hospital, Glasgow, Glasgow City, g12OYN, United Kingdom|Royal Marsden Hospital (Chelsea), London, Kensington And Chelsea, SW3 6JJ, United Kingdom|University College London Hospital, London, London, City Of, NW1 2PG, United Kingdom|Royal Marsden Hospital (Sutton), London, Sutton, SM2 5PT, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/37/NCT04211337/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/37/NCT04211337/SAP_001.pdf"
